Screen LibrarySurgery in rheumatic and musculoskeletal disease /
"Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing...
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | ; ; ; ; |
| Published: |
Elsevier,
|
| Publisher Address: | Amsterdam, Netherlands : |
| Publication Dates: | [2018] |
| Literature type: | eBook |
| Language: | English |
| Series: |
Handbook of systemic autoimmune diseases ;
volume 15 |
| Subjects: | |
| Online Access: |
https://www.sciencedirect.com/science/handbooks/15715078/15 https://www.sciencedirect.com/handbook/handbook-of-systemic-autoimmune-diseases/vol/15/suppl/C |
| Summary: |
"Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing the use of surgery in the treatment of specific diseases in various areas (cardiology, gastroenterology, orthopedics, neurology. etc.) and the possible difficulties and complications. The final five chapters deal with the possible complications arising during the course of biological and non-biological treatment, also providing recommendation concerning their management. International in scope, the list of more than 20 contributors from Europa and America reads like a who's who of clinical researchers in the field. Written by leading international clinical/surgical and scientific experts on surgical problems in SADsProvides a practical guide to the safer use of surgery in patients with autoimmune diseasesIncludes a number of problems and recommendations that cannot be found in other booksDesigned as a 'guide to clinical practice' for surgical interventions required by patients with SADsGives a comprehensive review of the available surgical options"-- |
| Carrier Form: | 1 online resource(xvi, 212 pages). |
| Bibliography: | Includes bibliographical references and index. |
| ISBN: |
9780444638885 0444638881 |
| Index Number: | RD605 |
| CLC: | R593.2 |
| Contents: |
Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab) |